Literature DB >> 1960301

Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

L C Wallentin1.   

Abstract

In this study, 796 men with unstable coronary artery disease (that is, unstable angina or non-Q wave myocardial infarction) were randomized to double-blind placebo-controlled treatment with aspirin (75 mg/day). The long-term efficacy was judged from the occurrence of myocardial infarction or death or severe angina necessitating referral to coronary angiography. The risk of myocardial infarction or death was reduced during aspirin treatment--after 1 year, the risk ratio was 0.52 (confidence interval 0.37 to 0.72). Severe angina necessitating referral to coronary angiography was less common during aspirin therapy--after 3 months, the risk ratio was 0.59 (0.42 to 0.84) and after 1 year 0.71 (0.56 to 0.91). The combined event rate of myocardial infarction or death or referral to coronary angiography was reduced; after 3 months, the risk ratio was 0.44 (0.30 to 0.66) and after 1 year 0.65 (0.54 to 0.79). The 75-mg aspirin dose was well tolerated and had a high level of patient compliance. Treatment with aspirin (75 mg/day) should be recommended to all men for greater than or equal to 3 months after an episode of unstable coronary artery disease. Long-term therapy should be considered if there are no contraindications or side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960301     DOI: 10.1016/0735-1097(91)90489-v

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

Review 1.  Routine invasive versus conservative management strategies in acute coronary syndrome: time for a "hybrid" approach.

Authors:  Pravin Pratap; Sameer Gupta; Michael Berlowitz; Michael Berlowtiz
Journal:  J Cardiovasc Transl Res       Date:  2011-12-13       Impact factor: 4.132

2.  Antiplatelet therapy in acute coronary syndromes.

Authors:  Colin M Barker; Matthew J Price
Journal:  Curr Cardiol Rep       Date:  2008-07       Impact factor: 2.931

Review 3.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 4.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-04-25

Review 5.  [Therapy strategies for acute coronary syndrome and after coronary interventions. Antiplatelet agents and anticoagulants].

Authors:  D Divchev; C Nienaber; H Ince
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

6.  Acute coronary syndromes in the United States and United Kingdom: a comparison of approaches. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

Authors:  P C Adams; J S Skinner; M Cohen; R McBride; V Fuster
Journal:  Clin Cardiol       Date:  1998-05       Impact factor: 2.882

Review 7.  Nitrates for unstable angina.

Authors:  U Thadani; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

8.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 9.  Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review.

Authors:  Helen Gaskell; Sheena Derry; R Andrew Moore
Journal:  BMC Geriatr       Date:  2010-09-29       Impact factor: 3.921

Review 10.  Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Authors:  Shailja V Parikh; Ellen C Keeley
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.